Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Pricing Reform Puts Cancer Drug Innovation At Risk, Drug Leaders Warn

Executive Summary

Merck & Co. CEO Rob Davis, Regeneron president George Yancopoulos, Pfizer R&D president Mikael Dolsten and others weighed in at the Galien Forum on the potential impact of the US Inflation Reduction Act on innovation.

You may also be interested in...



Alkermes To Spin Out Oncology Business, Says Inflation Reduction Act Boosts Its Value

After a year of strong commercial performance for Lybalvi and with IL-2 drug nemvaleukin in registration-enabling studies, Alkermes is ready to separate its neuroscience and oncology businesses. 

Alkermes To Spin Out Oncology Business, Says Inflation Reduction Act Boosts Its Value

After a year of strong commercial performance for Lybalvi and with IL-2 drug nemvaleukin in registration-enabling studies, Alkermes is ready to separate its neuroscience and oncology businesses. 

President Bio-den? Executive Order Highlights Value Of Biotech – But Doesn’t Change Pricing Message

The White House is playing up a new initiative to support ‘biotechnology and biomanufacturing.’ The focus on innovation is always a welcome theme – but it does not signal any change in the emphasis on cutting drug pricing in the Biden Administration.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147302

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel